DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Amevive (Alefacept) - Summary

 
 



AMEVIVE SUMMARY

AMEVIVE® (alefacept) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH 2 and CH 3 domains) portion of human IgG1. Alefacept is produced by recombinant DNA technology in a Chinese Hamster Ovary (CHO) mammalian cell expression system.

AMEVIVE® is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.


See all Amevive indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Amevive (Alefacept)

CHMP Recommends Skilarence for Psoriasis
Source: Medscape Dermatology Headlines [2017.04.21]
The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended granting marketing approval for Skilarence for treatment of psoriasis.
International Approvals

Valeant Prices Psoriasis Treatment at $3,500 Per Month
Source: Medscape Medical News Headlines [2017.04.21]
Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017.
Reuters Health Information

Psoriasis Tied to Higher Risk of Uveitis
Source: Medscape Medical News Headlines [2017.04.21]
People with psoriasis have an increased risk of developing uveitis, according to Taiwan researchers.
Reuters Health Information

Risankizumab More Effective in Psoriasis Than Ustekinumab in Early Trial
Source: Medscape Allergy & Clinical Immunology Headlines [2017.04.19]
Selective inhibition of IL-23 with risankizumab may be more effective in treating psoriasis than the less specific ustekinumab; more studies are needed to confirm results and assess.
Medscape Medical News

Tofacitinib for Rheumatoid Arthritis and Plaque Psoriasis
Source: Medscape Orthopaedics Headlines [2017.04.17]
Review the latest data on the oral immunosuppressant tofacitinib, recently approved for the treatment of rheumatoid arthritis, and currently in Phase III trials for treating chronic plaque psoriasis.
Skin Therapy Letter

more news >>

Published Studies Related to Amevive (Alefacept)

Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. [2009.12]
BACKGROUND: Evidence from clinical trials supports the use of alefacept for the treatment of patients with chronic plaque psoriasis, either as monotherapy or combined with other treatment modalities. OBJECTIVE: AWARE (Amevive Wisdom Acquired from Real-World Evidence) is a multicenter, observational, phase IV Canadian registry of psoriasis patients treated with alefacept... CONCLUSION: Alefacept is commonly added to other antipsoriatic therapies in a broad population of real-world chronic plaque psoriasis patients in Canada and may allow for dosage reduction or discontinuation of concomitant systemic agents or phototherapy.

Efficacy outcomes in patients using alefacept in the AWARE study. [2009.12]
BACKGROUND: Alefacept has demonstrated efficacy in clinical trials of patients with chronic plaque psoriasis, either as monotherapy or combined with other treatment modalities such as phototherapy. OBJECTIVE: AWARE (Amevive Wisdom Acquired from Real-World Evidence) is a multicenter, observational, phase IV Canadian registry of psoriasis patients treated with alefacept... CONCLUSION: A single course of alefacept therapy improved outcomes in this broad population of real-world chronic plaque psoriasis patients.STUDY LIMITATIONS:The limitations of this study include its nonrandomized, noncontrolled, noncomparative design, which allowed multiple different treatment approaches across all patients. The rating scales used in this study have not been previously validated, and ranges were assigned to baseline control and response data that are not specifically defined. Clinicians did not receive specific training in using these scales; therefore, interrater variability could not be assessed.

Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. [2009.11]
OBJECTIVE: To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA)...

Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. [2009.03]
BACKGROUND: A single course of alefacept intramuscularly in combination with methotrexate (MTX) was effective in treating both psoriasis and psoriatic arthritis (PsA). OBJECTIVE: We sought to determine the efficacy and safety of an additional course of alefacept intramuscularly in combination with MTX in patients with PsA... CONCLUSIONS: Patients with psoriasis and PsA on stable doses of MTX derive benefit for both conditions from one or more courses of alefacept, with further benefit in PsA apparent after a second course of treatment. No additional toxicity was observed.

Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. [2007.08]
OBJECTIVE: To determine whether the addition of 311-nm narrowband UV-B (NB UV-B) phototherapy accelerates and improves the therapeutic efficacy of alefacept, a biological antipsoriatic drug approved for the treatment of moderate to severe psoriasis... CONCLUSIONS: In this randomized half-side comparison of alefacept with and without phototherapy for psoriasis, alefacept with NB UV-B phototherapy accelerated and improved the clearance of psoriasis. This suggests a promising future for this combination as antipsoriatic therapy.

more studies >>

Clinical Trials Related to Amevive (Alefacept)

AMEVIVEďż˝ Pregnancy Registry [Terminated]
This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVEŽ Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses exposed to AMEVIVEŽ in order to detect any potential increase in the risk of major birth defects. The AMEVIVEŽ Pregnancy Exposure Registry is sponsored by Astellas Pharma Global Development and will be managed by INC Research. The Registry will be monitored by an independent Advisory Committee of external experts in relevant specialties of teratology, epidemiology, maternal and fetal medicine, and infectious disease medicine (external member details available upon request).

Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Terminated]
The study is a prospective, multi-centre, observational study designed to assess the long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic plaque psoriasis.

Long-Term One Year Use of Alefacept (Ameviveďż˝) in Moderate to Severe Chronic Plaque Type Psoriasis [Completed]
The purpose of this research study is to see how well the medication Alefacept (AmeviveŽ) works for continuous treatment of chronic plaque psoriasis. The US Food and Drug Administration (FDA) has approved Alefacept in an intermittent dosage schedule of 15 mg weekly injection for 12 weeks followed by 12 weeks off treatment.

Inducing Remission in Type 1 Diabetes With Alefacept [Completed]
The purpose of this trial is to test whether a drug called alefacept will slow or halt destruction of the beta cells in the pancreas. If the destruction of the beta cells is stopped, the patients might be able to produce insulin on their own longer, which could stop or slow the progression of their type 1 diabetes. This is a multi-center prospective, placebo-controlled, double-blind and randomized trial to investigate the ability of alefacept to protect residual beta cells from ongoing autoimmune destruction in adolescents and young adults with newly diagnosed Type 1 Diabetes Mellitus (T1DM).

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers [Completed]

more trials >>

Reports of Suspected Amevive (Alefacept) Side Effects

OFF Label USE (14)Diabetes Mellitus (8)Kidney Transplant Rejection (7)Death (4)Antibody Test Positive (4)Myocardial Infarction (3)Cardiac Failure Congestive (3)Depression (2)Infectious Peritonitis (2)Cellulitis (2)more >>


Page last updated: 2017-04-21

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017